Celebrating Twenty Years of People Who Make ATS Special
Celebrating Twenty Years of People Who Make ATS Special Read More »
News Article
Cover Article: Celebrating Twenty Years of Science Advanced Targeting Systems (founded 22 Apr 1994)
Advanced Targeting Systems’ first product, 192-IgG-SAP, answered a long-sought request from behavioral neuroscientists: a neurotoxin for the cholinergic neurons of the basal forebrain. Over the years it has become the classic in the field and has changed the way that we think about those neurons and their role in learning and memory. Substance P-saporin (SP-SAP)
Targeting Stars: SFN Poster Winners
2000 – Robert Sloviter and Jennifer Martin used SSP-SAP (Cat# IT-11) 2001 – Mary Ann Greco used Orexin-SAP 2002 – Lique Coolen and William Truitt used SSP-SAP (Cat# IT-11) 2003 – Jill McGaughy used 192-IgG-Saporin (Cat# IT-01) 2004 – Michelle Pearson used IB4-SAP (Cat# IT-10) 2005 – W.Zhang used Dermorphin-SAP (Cat. #IT-12) and CCK-SAP (Cat. #IT-31) 2006 – Neelima Chauhan used mu
Targeting Stars: SFN Poster Winners Read More »
Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain
Contributed by Douglas A. Lappi, Ph.D., President/Chief Scientific Officer, Advanced Targeting Systems, San Diego, CA Substance P-Saporin (SP-SAP), ATS’s patented conjugate being developed for cancer pain therapy, has attracted a considerable amount of attention recently. Back-to-back publications, a press release and editorial were featured in the November issue of the journal Anesthesiology. The first article,
Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain Read More »
Cover Article: Role of spinal microglia in the development of morphine-induced hyperalgesia
Contributed by Francesco Ferrini (1) and Yves De Koninck (2,3) 1) Department of Veterinary Sciences, University of Turin,10095 Grugliasco, Turin, Italy 2) Institut universitaire en santé mentale de Québec, QC, G1J 2G3, Canada 3) Department of Psychiatry and Neuroscience, Université Laval, Québec, QC, G13 7P4, Canada Morphine-induced hyperalgesia and tolerance dramatically limit the use of
Targeting Article: Targeted Toxins, Optogenetics, and the BRAIN Initiative
Contributed by Brian J. Russell The newly invigorated BRAIN initiative (Brain Research through Advancing Innovative Neurotechnologies, also known as the Brain Activity Map Project) has placed a premium on understanding the role of each neuron within the human brain. This effort has been our focus for some time via our Targeted Toxin technology. From the
Targeting Article: Targeted Toxins, Optogenetics, and the BRAIN Initiative Read More »
Cover Article: Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits in an NGFr-lesioned mouse model
Contributed by Liu Y, Weick JP, Liu H, Krencik R, Zhang X, Ma L, Zhou GM, Ayala M, Zhang SC. Waisman Center, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA. and Human Anatomy and Histology, Fudan University Shanghai Medical School, Shanghai, China. Basal forebrain neurons including cholinergic neurons and GABA interneurons
Cover Article: Antibodies to glycosphingolipids: An attractive tool for targeted delivery of cytotoxic agents to tumor cells
Contributed by Jose Luis Daniotti, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC, UNC-CONICET), Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina. Glycosphingolipids (GSLs) are amphipathic molecules consisting of a ceramide lipid moiety linked to a glycan chain of variable length and structure. Among these are found the
Cover Article: Role of cholinergic neurons in the nucleus accumbens and their involvement in schizophrenic pathology
Contributed by François LaPlante. Dept of Psychiatry, McGill University, Montréal, QC, Canada A post-mortem reduction in the density of cholinergic interneurons in the ventral striatum or nucleus accumbens (N.Acc.) has been reported in schizophrenic brains.[1,2] In this region the cholinergic interneurons interact anatomically and functionally with the dopaminergic nerve terminals notably to dampen the effects
Cover Article: Partial basal forebrain cholinergic depletion leaves working memory susceptible to the effects of systemic inflammation
Contributed by Dr. Colm Cunningham, Trinity College, Institute of Neuroscience & School of Biochemistry and Immunology, Dublin, Ireland It is well established that peripheral inflammation can signal the intact CNS to bring about adaptive changes in behavior during the sickness response. However, during aging and dementia, the brain is particularly susceptible to the deleterious effects